EGFR and non-small cell lung carcinoma: The proliferation of Erlotinib-resistant NSCLC cells (H460/TKI-R) were inhibited when treated with AG1024 (IGF-1R-target), compared with those treated with continuous Erlotinib (EGFR-targeted) (Fig 1g) [9].